Standard BioTools
Standard BioTools Q1 Revenues Fall 19 Percent
In Q1 the company formerly known as Fluidigm completed a strategic evaluation process and closed a $250 million capital infusion from Casdin Capital and Viking Global Investors.
Fluidigm Obtains $250M Investment, Changing Name to Standard BioTools
The firm intends to simplify the design and execution of deep cell profiling, and standardize sample analysis with reproducible workflows and automation.